A 2021 study published in the New England Journal of Medicine showed that people on semaglutide lost 14.9% of their body weight over 68 weeks versus 2.4% in the placebo group
doi: 10.1177/1060028017689878 64 Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
Additionally, this paper explores the potential applications of GLP-1 receptor agonists (GLP-1RAs) in fields such as neuroprotection, anti-infection measures, the reduction of various types of inflammation, and the enhancement of cardiovascular function
This cautious approach can be attributed to the historical context of Rimonabant, a previously promising anti-obesity agent withdrawn from the market in 2008 due to severe psychiatric side effects 26
241 Rodent and human studies have produced evidence that GLP-1 therapies have antiatherosclerotic and angiogenic effects, and these therapies hindered the development of diabetic cardiomyopathy